Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Judy Dering"'
Autor:
Masashi Sanada, Hisae Karahashi, Charles Ginther, Christine Walsh, Hang Tran, Norihiko Kawamata, Seishi Ogawa, Dennis J. Slamon, James C. Pavelka, Yasuhito Nannya, Carl W. Miller, H. Phillip Koeffler, Beth Y. Karlan, Judy Dering, Daniel R. Scoles
Publikováno v:
Journal of Clinical Oncology. 26:2952-2958
Purpose To identify a biomarker of ovarian cancer response to chemotherapy. Patients and Methods Study participants had epithelial ovarian cancer treated with surgery followed by platinum-based chemotherapy. DNA and RNA were isolated from frozen tumo
Autor:
Gottfried E. Konecny, Diane Provencher, Noa Ben-Baruch, Jalid Sehouli, Paul Cottu, Chen Wang, Gabriele Feisel, Sylvie Jacod, Fritz Jänicke, Hsiao-Wang Chen, Beth Y. Karlan, Lynda D. Roman, Martin Pölcher, Paul Haluska, Vincent Houe, Matthias W. Beckmann, Judy Dering, Dennis J. Slamon, Isabelle Ray-Coquard, Achim Rody
Publikováno v:
Journal of Clinical Oncology. 32:5529-5529
5529 Background: IGF signaling has been implicated in the pathogenesis and progression of ovarian cancer (OC). Ganitumab (GAN; AMG 479) is an investigational, fully human, monoclonal antibody inhib...
Autor:
Boris Winterhoff, Chen Wang, Judy Dering, Ellen L. Goode, Lynn C. Hartmann, Gottfried E. Konecny, Hsiao-Wang Chen, Dennis J. Slamon, Charles Ginther, Sean C. Dowdy, Habib Hamidi, Paul Haluska, Kimberly R. Kalli, Karl C. Podratz, William A. Cliby
Publikováno v:
Journal of Clinical Oncology. 31:5510-5510
5510 Background: Transcriptional profiling of ovarian cancers has proven to be complex. As such it has been difficult to validate existing signatures across studies. Cancer Genome Atlas (TCGA) researchers have identified four molecular subtypes of hi
Autor:
Hsiao-Wang Cheng, Charles Ginther, Dennis J. Slamon, Lee Anderson, Erika von Euw, Richard S. Finn, Judy Dering, Veerauo Konkankit, Ke Wei Gong
Publikováno v:
Journal of Clinical Oncology. 30:8592-8592
8592 Background: Melanoma is the most aggressive form of skin cancer. Its management is evolving rapidly due to an improved understanding of the molecular heterogeneity and the development of effective, personalized targeted therapies. PLX4032 is a B
Autor:
M. Arbushites, A. Florance, Richard S. Finn, Judy Dering, G. T. Platek, S.R.D. Johnston, Maria Koehler, Michael F. Press
Publikováno v:
Journal of Clinical Oncology. 27:1018-1018
1018 Background: Lapatinib (Lap), an oral, dual inhibitor of EGFR/HER-2, is approved with capecitabine for treatment of HER-2+ MBC for recurrence after taxane, anthracycline, and trastuzumab-based therapy. Letrozole (Let) has activity in hormone-rece
Autor:
Judy Dering, Amrita Desai, Ondrej Kalous, DJ Slamon, Richard S. Finn, J. R. Hecht, E. Clark, Zev A. Wainberg, Charles Ginther, Adrian Anghel
Publikováno v:
Journal of Clinical Oncology. 26:14688-14688
14688 Background: Elevated levels of Src kinase have been implicated in the malignant potential of colorectal cancer. Dasatinib is an orally active, multi-targeted tyrosine kinase inhibitor of ABL ...
Autor:
L. S. Williams, Maria Koehler, Cristina Oliva, Zeba Aziz, Henry L. Gomez, M. Arbushites, A. Di Leo, Richard S. Finn, Zanete Zvirbule, Judy Dering
Publikováno v:
Journal of Clinical Oncology. 25:1011-1011
1011 Background: L is an oral tyrosine kinase inhibitor of EGFR/HER2, active as monotherapy and in combination for HER2-overexpressing advanced/metastatic breast cancer (BC). A Phase I study of L with paclitaxel (P) indicated no unexpected adverse ev
Autor:
Richard S. Finn, Judy Dering, M. South, Charles Ginther, John F. Forbes, Matthieu Rupin, Tim French, John R. Mackey, Michael F. Press, DJ Slamon
Publikováno v:
Journal of Clinical Oncology. 24:514-514
514 Background: Hormonal based therapy has long been the mainstay for treatment of ER+ breast cancer. ER+ PR- disease is now known to exhibit different clinical behavior compared to ER+PR+ disease. Recent data indicate that ER+PR- disease is characte